What was the main driver of revenue growth for IDEXX LABORATORIES in this quarter?

The primary driver of revenue growth was the Companion Animal Group (CAG) segment, which saw increased demand for companion animal diagnostics, including consumables, reference laboratory services, and veterinary software and imaging systems. Higher realized prices and increased testing volumes also contributed.

How did the company manage supply chain and inflationary pressures?

IDEXX Laboratories reported that disciplined infrastructure management and proactive engagement with suppliers and logistics partners helped mitigate the impact of supply chain constraints, product availability issues, and inflationary pressures. They also noted that price increases and productivity initiatives helped offset some of these effects on gross profit margins.

What is the outlook for Research and Development (R&D) spending?

Research and Development expenses saw a significant increase of 82.7% for the nine-month period compared to the prior year. This was primarily due to discrete investments for the acquisition of rights to use certain licensed technology, project costs, and higher personnel-related costs. This indicates a strategic focus on innovation and future product development.

How is the company managing its debt and liquidity?

IDEXX Laboratories maintained a strong liquidity position, with $99.2 million in cash and cash equivalents and $365.5 million in available borrowing capacity under its $1 billion credit facility as of September 30, 2022. The company also reported an increase in borrowings under its credit facility, which was used to fund operations and manage working capital needs. A subsequent event noted an incremental term loan of $250 million was obtained in October 2022.

IDXX 10-Q Quarterly Report Q3 FY2022 — Revenue, Net Income, EPS

Summary

IDEXX LABORATORIES INC /DE (IDXX) reported its third-quarter and nine-month results for the period ending September 30, 2022. The company demonstrated solid revenue growth, driven primarily by its Companion Animal Group (CAG) segment. Total revenue for the nine months increased to $2.54 billion, a 5.2% rise compared to the prior year, with organic revenue growth of 7.5% excluding currency impacts and acquisitions. While net income saw a decrease for the nine-month period, primarily due to increased research and development investments, the company maintained strong operational performance and a healthy gross profit margin. Looking ahead, IDEXX is navigating supply chain challenges and foreign currency headwinds but remains strategically positioned for continued growth, particularly within the companion animal healthcare market. The company's liquidity remains robust, supported by operating cash flows and available credit facilities, enabling ongoing investments in innovation and strategic acquisitions.

Financial Highlights

53 data points

Beta

Revenue

$841.66M

0.6% Gross Margin

Net Income

$180.94M

0.2% Net Margin

EPS (Diluted)

$2.15

Total Assets

$2.64B

Cash & Equivalents

$99.18M

Free Cash Flow

$151.31M

Financial Statements

Beta

Revenue	$841.66M
Cost of Revenue	$335.04M
Gross Profit	$506.63M
R&D Expenses	$48.01M
Operating Income	$244.83M
Interest Expense	$11.00M
Net Income	$180.94M
EPS (Basic)	$2.17
EPS (Diluted)	$2.15
Shares Outstanding (Basic)	83.25M
Shares Outstanding (Diluted)	84.11M

Key Highlights

1Total revenue for the nine months ended September 30, 2022, was $2.54 billion, a 5.2% increase year-over-year.
2Organic revenue growth for the nine months was 7.5%, driven by strong performance in the Companion Animal Group (CAG).
3CAG segment revenue increased by 6.4% for the nine months, reflecting solid demand for companion animal diagnostics and software services.
4Gross profit margin for the nine months improved slightly to 59.8% from 59.4% in the prior year, benefiting from price gains and productivity initiatives.
5Research and development expenses significantly increased by 82.7% for the nine months, largely due to investments in licensed technology.
6Net cash provided by operating activities decreased by $176 million for the nine months, impacted by higher inventory levels and R&D investments.
7The company ended the period with $99.2 million in cash and cash equivalents, and a $365.5 million borrowing availability under its $1 billion credit facility.

IDEXX LABORATORIES INC /DE Quarterly Report for Q3 Ended Sep 30, 2022

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions